Moderna Lowers 2025 Revenue Forecast but Beats Q3 Expectations
Moderna cut its 2025 revenue forecast due to weak U.S. COVID-19 vaccine sales but beat Wall Street’s Q3 estimates, lifting shares premarket.
/ 13 items
#MRNA↓
Moderna Explores Major Deal Options, Including Potential Buyout
Moderna is in discussions with large pharmaceutical companies about significant deals, including a possible buyout.
Moderna Abandons CMV Birth Defect Vaccine After Late-Stage Trial Failure
Moderna discontinues its cytomegalovirus vaccine development after Phase 3 trial shows only 6-23% efficacy, missing targets for preventing congenital birth defects in a major setback for the biotech company.
Shah Capital Urges Novavax Sale After COVID Vaccine Struggles Continue
Novavax's second-largest shareholder Shah Capital pushes for company sale, citing poor COVID vaccine sales and untapped potential worth $5 billion under larger pharma ownership.
Moderna Rises on Release of Positive Results for the Reformulated COVID Vaccine
New COVID vaccines from Moderna & Pfizer show strong protection against the dominant LP.8.1 variant. Moderna's Spikevax (for high-risk 6mo-64yrs & all 65+) boosted antibodies 8x. Pfizer's also effective. No new safety issues found.
Major Report Sparks Debate: Are COVID Vaccines Linked to Child Deaths?
Trump officials plan to link COVID vaccines to 25 child deaths using unverified VAERS data. This news dropped vaccine makers' shares. HHS calls it "pure speculation", while Moderna states its vaccine is rigorously monitored with no new safety concerns.